Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

PROSCA/BLADDR 2020 | Immunotherapy in prostate cancer

Emmanuel Seront • 7 Oct 2020
PROSCA/BLADDR 2020
Genitourinary Cancer Prostate Cancer

Emmanuel Seront, MD, PhD, Jolimont Hospital, La Louvière, Belgium, discusses the use of immunotherapies in prostate cancer including ongoing studies evaluating immunotherapy and PARP inhibitors. Dr Seront highlights the importance of identifying patients that are more likely to respond to immunotherapy. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Emmanuel Seront

RENALUT: 177Lu-PSMA-617 in metastatic pre-treated ccRCC
3:52
RENALUT: 177Lu-PSMA-617 in metastatic pre-treated ccRCC
Emmanuel Seront • 18 Oct 2025
Genomic testing in prostate cancer
1:29
Genomic testing in prostate cancer
Emmanuel Seront • 7 Oct 2020
Advances in non-metastatic castration-resistant prostate cancer
1:22
Advances in non-metastatic castration-resistant prostate cancer
Emmanuel Seront • 14 Oct 2020

Related Videos

Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
2:10
Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
Tian Zhang • 1 Jun 2026
Highlights in ADCs for bladder cancer at ASCO 2026
1:29
Highlights in ADCs for bladder cancer at ASCO 2026
Tian Zhang • 1 Jun 2026
EV plus pembrolizumab improves perioperative outcomes in muscle-invasive bladder cancer
3:36
EV plus pembrolizumab improves perioperative outcomes in muscle-invasive bladder cancer
Tian Zhang • 1 Jun 2026
Drug repurposing and trial challenges in rare renal medullary carcinoma
3:11
Drug repurposing and trial challenges in rare renal medullary carcinoma
Pavlos Msaouel • 30 May 2026
The content of VJOncology is intended for healthcare professionals